Oxycodone and hydrocodone are both semi-synthetic opioids prescribed for moderate to severe pain, and they work through the same primary mechanism: activating mu-opioid receptors in the brain and spinal cord. The practical differences between them come down to potency per milligram, the formulations they come packaged in, how your liver processes each one, and a regulatory history that has treated them quite differently despite their pharmacological kinship.
How They Compare in Strength
The single most cited difference is that oxycodone is roughly one-and-a-half times stronger than hydrocodone on a milligram-for-milligram basis. In equianalgesic dose charts used in emergency departments, 20 mg of oral oxycodone is considered equivalent to 30 mg of oral morphine, while 30 mg of oral hydrocodone is also equivalent to 30 mg of oral morphine.1PubMed Central. Morphine Equianalgesic Dose Chart in the Emergency Department That means if you switched from one drug to the other at the same dose, oxycodone would deliver a noticeably stronger effect. In practice, though, prescribers adjust the dose to match, so a patient receiving a properly dosed prescription of either drug should get a similar level of pain relief.
Head-to-head clinical trials bear this out. A double-blind trial in emergency-department patients with acute fractures found no meaningful difference in pain scores at 30 or 60 minutes between the two drugs when given at equivalent doses.2PubMed. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial A larger study of patients recovering from joint replacement surgery actually found slightly lower composite pain scores and lower total opioid use in the group receiving hydrocodone compared with the oxycodone group.3JAMA Network Open. Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty That result ran counter to the researchers’ own hypothesis, and it is a reminder that equianalgesic charts are rough guides, not exact predictions of how an individual will respond.
Why the Formulation Matters as Much as the Drug
For decades, most hydrocodone in the United States was prescribed as a combination product with acetaminophen (the active ingredient in Tylenol). Brand names like Vicodin and Norco are hydrocodone-acetaminophen combinations. Oxycodone, by contrast, has long been available both as a standalone drug (in immediate-release tablets and in the extended-release form OxyContin) and in combination with acetaminophen (Percocet). This packaging difference has real consequences for safety.
The acetaminophen issue is not trivial. A retrospective study of more than 900,000 commercially insured patients on immediate-release hydrocodone-acetaminophen found that roughly 15% were prescribed total daily acetaminophen doses exceeding 4 grams, which is the FDA-recommended ceiling.4PubMed. A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit Taking too much acetaminophen can cause acute liver failure, and opioid-acetaminophen combinations were a major contributor. In 2011, the FDA mandated that prescription combination products contain no more than 325 mg of acetaminophen per tablet. After that mandate took effect, the proportion of acute liver failure cases involving acetaminophen-opioid toxicity dropped from about 27% to roughly 5%.5PubMed Central. Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure
Extended-release hydrocodone formulations without acetaminophen have since become available, eliminating the liver toxicity risk that comes from the combination product.6PubMed Central. Extended-release hydrocodone – gift or curse? But the vast majority of hydrocodone prescriptions in the United States are still for combination products. If you are taking hydrocodone combined with acetaminophen and are also taking any other medication containing acetaminophen, like an over-the-counter cold remedy, you can accidentally exceed the safe daily dose. Oxycodone standalone formulations avoid this problem entirely.
How Your Liver Handles Each Drug
Both oxycodone and hydrocodone are processed primarily in the liver by two enzyme families. The enzyme CYP3A4 handles the major metabolic pathway for both, while CYP2D6 handles a secondary pathway that produces the more potent active metabolites. What differs is how important those metabolites are to the drug’s overall effect.
Hydrocodone’s CYP2D6-dependent metabolite is hydromorphone, which has far higher affinity for mu-opioid receptors than the parent drug. However, the amount of hydromorphone that actually accumulates in the blood is small, typically only about 3% to 5% of the hydrocodone concentration.7PMC. Hydrocodone, Oxycodone, and Morphine Metabolism and Drug–Drug Interactions – Section: Hydrocodone Metabolism CYP3A4, meanwhile, converts hydrocodone to norhydrocodone through a separate pathway.8PubMed Central. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes The fact that hydromorphone levels stay low helps explain why people with genetic differences in CYP2D6 activity do not show dramatically different responses to hydrocodone.9PubMed. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone
Oxycodone follows a broadly similar pattern but with a potentially more significant metabolite. CYP2D6 converts oxycodone to oxymorphone, which has 40 to 60 times higher mu-opioid receptor affinity than the parent compound.10European Journal of Pharmaceutical Sciences. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation In theory, genetic variation in CYP2D6 could make a bigger difference for oxycodone users. In practice, a recent study of postsurgical patients found that CYP2D6 metabolizer status was not meaningfully associated with pain control or opioid use for either hydrocodone or oxycodone, possibly because modern multimodal pain management (combining opioids with non-opioid painkillers, nerve blocks, and anti-inflammatories) dilutes the pharmacogenetic signal.11PubMed Central. CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone
Oxycodone also has a receptor profile that goes beyond what hydrocodone does. Mouse studies have shown that oxycodone can activate delta-opioid receptors in addition to the usual mu-opioid receptors, which may contribute to its central pain-relieving effects through a partially distinct pathway.12ScienceDirect. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice Whether this dual-receptor activity translates to a clinically noticeable difference in humans is still unclear, but it is one pharmacological distinction that separates the two drugs at a molecular level.
Abuse Liability and Subjective Effects
One area where the drugs appear to diverge is in how they make people feel beyond pure pain relief. A systematic review of double-blind, randomized studies scored oxycodone as having high abuse liability based on its likability ratings and a relative lack of negative subjective effects. Hydrocodone, by comparison, showed no consistent difference from morphine in abuse liability.13PubMed Central. Likeability and Abuse Liability of Commonly Prescribed Opioids That finding aligns with a common clinical impression that oxycodone produces a somewhat “cleaner” euphoria with fewer side effects like nausea or sedation at equivalent analgesic doses.
A study of prescription opioid abusers that directly compared the three drugs found that oxycodone was roughly equipotent to or slightly more potent than hydrocodone in terms of abuse-related effects. The study also concluded that analgesic potency ratios (the kind used in clinical dose-conversion charts) do not reliably predict differences in abuse liability.14Drug and Alcohol Dependence. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers In other words, the drugs are closer in abuse potential than the roughly 1.5-to-1 potency ratio would suggest.
These findings had real-world consequences. OxyContin became the focus of the early prescription opioid crisis, and its manufacturer eventually reformulated it as an abuse-deterrent product in 2010. The reformulation used technology that made the tablet hard to crush for snorting and gummy in water to prevent injection. Past-month abuse of OxyContin dropped from about 45% of a surveillance sample before reformulation to about 26% afterward, but a substantial portion of users simply migrated to other opioids or heroin.15JAMA Psychiatry. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin Newer abuse-deterrent formulations have since been developed for both oxycodone and hydrocodone products, though not all technologies work equally well against all methods of tampering.16PubMed Central. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access
How Scheduling Changed the Landscape
Until October 2014, hydrocodone combination products (like Vicodin) were classified as Schedule III controlled substances in the United States, while oxycodone had always been Schedule II. The practical difference was enormous. Schedule III drugs could be called in by phone, refilled up to five times without a new prescription, and prescribed by mid-level providers with fewer restrictions. Schedule II drugs required a new written or electronic prescription every time, with no refills.
The DEA rescheduled hydrocodone combination products to Schedule II in October 2014, and prescribing patterns shifted quickly. In the 12 months after rescheduling, dispensed hydrocodone combination prescriptions fell by about 22%, and dispensed tablets dropped by about 16%. Refills accounted for nearly three-quarters of the decline and were essentially eliminated by early 2015.17JAMA Internal Medicine. Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing Over a longer study window, hydrocodone dispensing fell by more than 30%, though some substitution toward codeine, oxycodone, and morphine prescriptions partially offset the decline.18PubMed Central. The Impact of Hydrocodone Rescheduling on Utilization, Abuse, Misuse, and Overdose Deaths
The effects were not uniform across medical specialties. In Ohio, internists saw the largest absolute decrease in hydrocodone prescribing, while emergency physicians saw essentially no change, likely because ER prescriptions were already short-course and rarely involved refills.19PubMed Central. Effects of Rescheduling Hydrocodone on Opioid Prescribing in Ohio The rescheduling achieved its primary goal of reducing overall opioid prescribing volume, but it also revealed a recurring pattern in opioid policy: tightening access to one drug can push some prescribers and patients toward alternatives, not always in predictable ways.
Side Effects People Actually Notice
Both drugs share the standard opioid side-effect profile: constipation, nausea, drowsiness, dizziness, and itching. At equivalent pain-relieving doses, neither drug is dramatically worse than the other for most patients. But there are tendencies worth knowing about.
Hydrocodone is often described by patients and clinicians as somewhat more sedating, possibly because the commonly prescribed combination with acetaminophen tends to be taken at doses that produce more central-nervous-system depression relative to the analgesic effect. Oxycodone is sometimes perceived as causing less nausea and less mental cloudiness at equivalent analgesic doses, which matches its higher subjective-likability scores in abuse-liability research. These are generalizations, and individual variation is wide: some people tolerate one drug perfectly and feel terrible on the other, for reasons that likely involve genetics, liver enzyme activity, and receptor sensitivity that no standard test can predict in advance.
Constipation, the most reliably universal opioid side effect, is roughly comparable between the two. Neither has a demonstrated advantage in bowel function at equivalent analgesic doses. For patients on chronic therapy, the constipation issue often matters more than subtle differences in euphoria or sedation, and it applies equally to both drugs.
Kidney Disease and Dose Adjustments
Opioid choice gets more complicated for people with impaired kidney function. Oxycodone and its active metabolites are cleared through the kidneys, and in patients with chronic kidney disease, peak plasma concentrations can be roughly 50% higher than in people with normal kidney function.20Therapeutics and Clinical Risk Management. Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists The drug can still be used, but clinicians typically start at a low dose, around 2.5 to 5 mg every four to six hours, and monitor closely.21PubMed Central. Opioid Management in Older Adults with Chronic Kidney Disease: A Review
Hydrocodone faces similar limitations in kidney disease because its metabolites also depend on renal clearance, but it receives somewhat less focused attention in the renal-dosing literature, in part because most prescribing guidelines for kidney patients were written during the era when hydrocodone was considered a less potent Schedule III drug and was frequently used as a first-line choice. For patients on dialysis, oxycodone has been studied and appears to be partially removed during hemodialysis sessions due to its low molecular weight, which can actually work in the patient’s favor by preventing accumulation between treatments.20Therapeutics and Clinical Risk Management. Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists
Extended-Release Formulations and How They Differ
Both drugs are available in extended-release forms designed to provide 12 to 24 hours of pain control from a single dose. OxyContin (extended-release oxycodone) was the first widely prescribed extended-release opioid and remains the most well-known. Its current formulation uses a technology called RESISTEC that makes the tablet difficult to crush and turns gummy in water, intended to prevent people from snorting or injecting it. However, it still carries a boxed warning against crushing or chewing because doing so releases the full dose at once.16PubMed Central. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access
Extended-release hydrocodone (branded as Hysingla ER and Vantrela ER, among others) came to market later. One extended-release oxycodone product, Xtampza ER, uses a different abuse-deterrent technology that allows the drug to retain its extended-release properties even when chewed or crushed, making it the only extended-release opioid without a boxed warning against those specific manipulations.16PubMed Central. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access In real-world use, extended-release hydrocodone doses tend to stabilize around 60 mg once daily, with patients requiring less rescue medication over time.22PubMed Central. Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials
Cost and insurance coverage can make the choice between extended-release products for you. Abuse-deterrent formulations tend to be considerably more expensive than generic immediate-release versions of either drug, and insurance coverage varies widely. For many patients with chronic pain who need long-acting opioid therapy, the decision between oxycodone and hydrocodone extended-release products hinges less on pharmacology than on which formulation their insurer will actually cover.